Table of Contents
ISRN Oncology
Volume 2012 (2012), Article ID 947831, 5 pages
Clinical Study

Parameters of Blood Count and Tumor Markers in Patients with Borderline Ovarian Tumors: A Retrospective Analysis and Relation to Staging

1Discipline of Gynecology and Obstetrics, Oncological Research Institute (IPON), Federal University of Triângulo Mineiro, 38025-440 Uberaba, MG, Brazil
2Discipline of Pharmacology, Federal University of Triângulo Mineiro, 38025-440 Uberaba, MG, Brazil

Received 16 January 2012; Accepted 20 February 2012

Academic Editor: A. E. Bilsland

Copyright © 2012 Rosekeila Simões Nomelini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The aim of this paper was to evaluate the parameters of blood count and tumor markers in borderline ovarian tumors. We evaluated 21 patients who had confirmed histopathologic diagnosis of borderline ovarian tumor. We recorded age, parity, tumor type, stage of cancer, serum levels of tumor markers (CA-125, CA-15.3, CA-19.9, CEA, AFP), and the parameters of blood count, fasting glucose, disease-free survival and overall. The patients were divided into two groups, stage IA ( 𝑛 = 1 3 ) and stage IB-IIIC ( 𝑛 = 8 ). The unpaired t-test and Fisher's exact test were used, with P values of less than 0.05 being considered to indicate statistical significance. Levels of red blood cells, hematocrit, and hemoglobin were significantly higher in stage IA when compared with stage IB-IIIC ( 𝑃 < 0 . 0 5 ). The levels of tumor marker CEA had a tendency to be higher in the group stage IB-IIIC (0.08). Abnormal levels of CEA and CA-19.9 were found more frequently in stages IB-IIIC. Therefore, parameters of blood count, CEA, and CA-19.9 should be targeted for further research in identifying prognostic factors in borderline tumors.